Nanjing Chia-tai Tianqing Pharmaceutical

This study tests a new drug called NTB003 for people with thyroid eye disease, a condition that can cause bulging eyes and discomfort. The trial will include 74 adults aged 18-75 with active disease. Researchers will check if the drug safely reduces eye bulging and other symptoms…

This Phase 3 study tests an experimental oral drug, NTQ5082, for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if the drug can raise hemoglobin levels enough to avoid blood transfusions. About 78 adu…

This study looks at the long-term safety and effectiveness of NTQ5082 capsules for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. About 78 adults who have already benefited from NTQ5082 or are on a standard treatment wi…

This phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop cancer growth in people with advanced HR+/HER2- breast cancer that has specific genetic changes (PIK3CA/AKT1/PTEN). About 210 adults whose cancer worse…